Age-specific survival trends and life-years lost in women with breast cancer 1990–2016: the NORDCAN survival studies

References

• Larønningen S, Ferlay J, Bray F, et al. NORDCAN: cancer incidence, mortality, prevalence and survival in the Nordic countries, version 9.1 (27.09.2021) [Internet]. Association of the Nordic Cancer Registries. Oslo, Norway: Cancer Registry of Norway. 2021; [cited 2022 Feb 3]. https://nordcan.iarc.fr/
   Google Scholar
• Lundberg FE, Andersson TM-L, Lambe M, et al. Trends in cancer survival in the Nordic countries 1990–2016: the NORDCAN survival studies. Acta Oncol. 2020;59(11):1266–1274.
   PubMed Web of Science ®Google Scholar
• Tryggvadóttir L, Gislum M, Bray F, et al. Trends in the survival of patients diagnosed with breast cancer in the Nordic countries 1964–2003 followed up to the end of 2006. Acta Oncol. 2010;49(5):624–631.
   PubMed Web of Science ®Google Scholar
• Land LH, Dalton SO, Jensen M-B, et al. Impact of comorbidity on mortality: a cohort study of 62,591 Danish women diagnosed with early breast cancer, 1990–2008. Breast Cancer Res Treat. 2012;131(3):1013–1020.
   PubMed Web of Science ®Google Scholar
• Engholm G, Ferlay J, Christensen N, et al. NORDCAN – a Nordic tool for cancer information, planning, quality control and research. Acta Oncol. 2010;49(5):725–736.
   PubMed Web of Science ®Google Scholar
• Pukkala E, Engholm G, Højsgaard Schmidt LK, et al. Nordic cancer registries – an overview of their procedures and data comparability. Acta Oncol. 2018;57(4):440–455.
   PubMed Web of Science ®Google Scholar
• Laugesen K, Ludvigsson JF, Schmidt M, et al. Nordic health registry-based research: a review of health care systems and key registries. Clin Epidemiol. 2021;13:533–554.
   PubMed Web of Science ®Google Scholar
• Lambert PC, Dickman PW, Rutherford MJ. Comparison of different approaches to estimating age standardized net survival. BMC Med Res Methodol. 2015;15(1):64.
   PubMed Web of Science ®Google Scholar
• Royston P, Lambert PC. Flexible parametric survival analysis using Stata: beyond the Cox model. College Station (TX): Stata Press; 2011. [Database]
   Google Scholar
• Syriopoulou E, Mozumder SI, Rutherford MJ, et al. Robustness of individual and marginal model-based estimates: a sensitivity analysis of flexible parametric models. Cancer Epidemiol. 2019;58:17–24.
   PubMed Web of Science ®Google Scholar
• Andersson TM-L, Rutherford MJ, Møller B, et al. Reference adjusted loss in life expectancy for population-based cancer patient survival comparisons – with an application to colon cancer in Sweden. Cancer Epidemiol Biomarkers Prev. 2022;31(9):1726.
   Web of Science ®Google Scholar
• Andersson TM-L, Dickman PW, Eloranta S, et al. Estimating the loss in expectation of life due to cancer using flexible parametric survival models. Stat Med. 2013;32(30):5286–5300.
   PubMed Web of Science ®Google Scholar
• Lambert PC, Andersson TM-L, Rutherford MJ, et al. Reference-adjusted and standardized all-cause and crude probabilities as an alternative to net survival in population-based cancer studies. Int J Epidemiol. 2020;49(5):1614–1623.
   PubMed Web of Science ®Google Scholar
• Stata Corp LLC. Stata statistical software: release 17. College Station (TX): Stata Corp LLC; 2021.
   Google Scholar
• Lambert PC, Royston P. Further development of flexible parametric models for survival analysis. Stata J. 2009;9(2):265–290.
   Web of Science ®Google Scholar
• Probst HB, Hussain ZB, Andersen O. Cancer patient pathways in Denmark as a joint effort between bureaucrats, health professionals and politicians—a National Danish project. Health Policy. 2012;105(1):65–70.
   PubMed Web of Science ®Google Scholar
• Ejlertsen B, Offersen BV, Overgaard J, et al. Forty years of landmark trials undertaken by the Danish Breast Cancer Cooperative Group (DBCG) nationwide or in international collaboration. Acta Oncol. 2018;57(1):3–12.
   PubMed Web of Science ®Google Scholar
• Baban CK, Devane L, Geraghty J. Change of paradigm in treating elderly with breast cancer: are we undertreating elderly patients? Ir J Med Sci. 2019;188(2):379–388.
   PubMed Web of Science ®Google Scholar
• Møller S, Jensen M-B, Ejlertsen B, et al.; Danish Breast Cancer Cooperative Group. The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise. Acta Oncol. 2008;47(4):506–524.
   PubMed Web of Science ®Google Scholar
• Lagerlund M, Åkesson A, Zackrisson S. Population-based mammography screening attendance in Sweden 2017–2018: a cross-sectional register study to assess the impact of sociodemographic factors. Breast. 2021;59:16–26.
   PubMed Web of Science ®Google Scholar
• Jacobsen KK, von Euler Chelpin M, Vejborg I, et al. Impact of invitation schemes on breast cancer screening coverage: a cohort study from Copenhagen, Denmark. J Med Screen. 2017;24(1):20–26.
   PubMed Web of Science ®Google Scholar
• Sebuødegård S, Sagstad S, Hofvind S. [Attendance in the Norwegian Breast Cancer Screening Programme]. Tidsskr Nor Laegeforen. 2016;136(17):1448–1451.
   PubMedGoogle Scholar
• Anttila A, Lehtinen M, Mäki S, et al. Breast Cancer Screening Programme – annual review 2021 [Internet]. Finnish Cancer Registry. [cited 2022 Feb 18]; https://cancerregistry.fi/screening/breast-cancer-screening/.
   Google Scholar
• Sigurdsson K, Ólafsdóttir EJ. Population-based service mammography screening: the Icelandic experience. Breast Cancer. 2013;5:25.
   Google Scholar
• Andersson TM-L, Engholm G, Pukkala E, et al. Avoidable cancers in the Nordic countries – the impact of alcohol consumption. Eur J Cancer. 2018;103:299–307.
   PubMed Web of Science ®Google Scholar
• Andersson TM-L, Engholm G, Lund ASQ, et al. Avoidable cancers in the Nordic countries—the potential impact of increased physical activity on postmenopausal breast, Colon and endometrial cancer. Eur J Cancer. 2019;110:42–48.
   PubMed Web of Science ®Google Scholar
• Andersson TM-L, Weiderpass E, Engholm G, et al. Avoidable cancer cases in the Nordic countries – the impact of overweight and obesity. Eur J Cancer. 2017;79:106–118.
   PubMed Web of Science ®Google Scholar
• Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet. 2019;394(10204):1159–1168.
   PubMed Web of Science ®Google Scholar
• Anderson WF, Rosenberg PS, Petito L, et al. Divergent estrogen receptor-positive and -negative breast cancer trends and etiologic heterogeneity in Denmark. Int J Cancer. 2013;133(9):2201–2206.
   PubMed Web of Science ®Google Scholar
• Allemani C, Matsuda T, Di Carlo V, et al.; CONCORD Working Group. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023–1075.
   PubMed Web of Science ®Google Scholar
• Sant M, Chirlaque Lopez MD, Agresti R, et al.; EUROCARE-5 Working Group. Survival of women with cancers of breast and genital organs in Europe 1999–2007: results of the EUROCARE-5 study. Eur J Cancer. 2015;51(15):2191–2205.
   PubMed Web of Science ®Google Scholar
• Minicozzi P, Innos K, Sánchez M-J, et al.; EUROCARE-5 Working Group. Quality analysis of population-based information on cancer stage at diagnosis across Europe, with presentation of stage-specific cancer survival estimates: a EUROCARE-5 study. Eur J Cancer. 2017;84:335–353.
   PubMed Web of Science ®Google Scholar